Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.

NCT07864480 is registered in ClinicalTrials.gov with Southeast Retina Center, Georgia as lead sponsor.

NCT NCT07864480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07864480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.
Lead sponsor
Southeast Retina Center, Georgia
Phase
Phase 4
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
December 31, 2029
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetic retinopathy, proliferative diabetic retinopathy